Table 4.

Polymeric Nanocarrier Hydrogels for Drug Delivery

Hydrogel Composition	Nanocarrier Composition	Drug	Disease	Release	Release Profile	Method of Administration	Ref.
GelMA, chitosan	Chitosan	BSA-bFGF	Promotion of angiogenesis	Biodegradation and crosslinking degree of the hydrogel enable sustained release of drug	Cumulative release reaches 90% and is sustained for 14 days in vitro	N/A	(Azizian et al., 2018)
Chitosan, gelatin	Chitosan	BSA-bFGF	Delivery to cells for enhanced growth	Sustained release enhanced by Chiotosan-gelatin scaffold which acts as a second barrier to drug release	Cumulative release reaches 100% at 50 hours in vitro	N/A	(Modaresifar et al., 2017)
Chitosan	Chitosan	BMP-2 plasmid DNA	Bone defects	Thermoresponsivity and degradation drive drug release	N/A	Implantation	(H. Li et al., 2017)
Acrylamide, poly(ethylene glycol) dimethacrylate, polyvinyl alcohol	Poly(lactic-co-glycolic acid)	Ciprofloxacin	Infection	Hydrogel degradation and diffusion of drug from nanoparticles enable controlled drug release	Cumulative Cipro release from blank gels reaches ~94% in 12 hours, is slowed to 88.2% in 72 hours with nanoparticle gels	Topical	(Y. Zhang et al., 2016)
Poly lactic acid, polycaprolactone	Gelatin	Metformin	Bone defects	Sustained release enhanced by PLA/PCL scaffold which acts as a second barrier to drug release	Cumulative MET release from nanocarrier scaffolds is decreased over 14 days compared to release from nanocarriers alone	Implantation	(Shahrezaee et al., 2018)
Cellulose acetate/poly(lactic acid)	Gelatin	Citalopram	Nerve defects	Nanocarrier-coated scaffolds exhibit increased biodegradability, which facilitates drug release	N/A	Implantation	(Naseri-Nosar et al., 2017)